Eli Lilly (LLY) said Wednesday its Surmount-5 phase 3b clinical study showed that Zepbound provided a 47% "greater relative weight loss" in comparison to Novo Nordisk's (NVO) Wegovy.
Zepbound, Eli Lilly's weight-loss drug, resulted in a "superior" weight reduction of 20.2% against Wegovy's 13.7%, the company added.
Eli Lilly's stock rose 2.3% in recent Wednesday premarket activity, while Novo Nordisk's shares were little changed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.